NDATOPICALGEL
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
NAFTIN (naftifine hydrochloride) by Enterprise Therapeutics is 12. Approved for interdigital tinea pedis caused by the organisms trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum. First approved in 2013.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAFTIN (naftifine hydrochloride) is a topical antifungal gel belonging to the allylamine class, approved in 2013 for treating interdigital tinea pedis. It works by inhibiting the enzyme squalene 2,3-epoxidase, disrupting fungal sterol biosynthesis and causing ergosterol depletion. The drug demonstrates strong penetration into the stratum corneum with proven efficacy against Trichophyton rubrum, T. mentagrophytes, and Epidermophyton floccosum.
Peak6.6 years to LOE
Product is in peak commercial stage with stable market presence, though team size and growth investments are likely being managed conservatively given approaching patent expiration.
Mechanism of Action
12.1 Mechanism of Action NAFTIN Gel is a topical antifungal drug [see ] . 12.2 Pharmacodynamics The pharmacodynamics of NAFTIN Gel have not been established . 12.3 Pharmacokinetics In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in…
Worked on NAFTIN at Enterprise Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.